Affordable Access

Use of Linagliptin for the Management of Medicine Department Inpatients with Type 2 Diabetes in Real-World Clinical Practice (Lina-Real-World Study)

Authors
  • Pérez-Belmonte, Luis M.
  • Gómez-Doblas, Juan J.
  • Millán-Gómez, Mercedes
  • López-Carmona, María D.
  • Guijarro-Merino, Ricardo
  • Carrasco-Chinchilla, Fernando
  • de Teresa-Galván, Eduardo
  • Jiménez-Navarro, Manuel
  • Bernal-López, Rosa
  • Gómez-Huelgas, Ricardo
Publication Date
Sep 11, 2018
Source
MDPI
Keywords
Language
English
License
Green
External links

Abstract

200 mg/dL (standardized difference = 0.021), or treatment failures (standardized difference = 0.011). Patients on basal-bolus insulin received higher total insulin doses and a higher daily number of injections (standardized differences = 0.298 and 0.301, respectively). Basal and supplemental rapid-acting insulin doses were similar (standardized differences = 0.003 and 0.012, respectively). There were no differences in hospital stay length (standardized difference = 0.003), hypoglycaemic events (standardized difference = 0.018), or hospital complications (standardized difference = 0.010) between groups. This study shows that in real-world clinical practice, the linagliptin-basal insulin regimen was as effective and safe as the standard basal-bolus regimen in non-critical patients with type 2 diabetes with mild to moderate hyperglycaemia treated at home without injectable therapies.

Report this publication

Statistics

Seen <100 times